Company profile

Bristol-Myers Squibb

Diversified pharma

BMY · NYSE · USA

Share price · BMY

$66.05+8.74 (+15.25%) 3M

close as of 2026-08-18 · 24h delayed · vol 6.6M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(47 total)
47Total Assets
19Approved
11Phase 3 / Filed
17Phase 1–2 / Early
17Diseases
Quick filter:
Showing 47 of 47 assets
Target & Modality
Abatacept(Orencia)
Approved
CD80/CD86 (CTLA-4-Ig) · Undisclosed / early pipeline · CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsProtein / enzyme therapeutic
Psoriatic ArthritisRheumatoid Arthritis
Aripiprazole (Abilify)(Abilify)
Approved
Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule
Schizophrenia
Azacitidine
Approved
DNMT1 (DNA methyltransferase 1)Small molecule
Acute Myeloid Leukemia
deucravacitinib(Sotyktu)
Approved
TYK2Small molecule
Psoriatic ArthritisAtopic DermatitisPsoriasisSystemic Lupus Erythematosus
Elotuzumab
Approved
SLAMF7 (CS1/CD319)Monoclonal antibody
Multiple Myeloma
Enasidenib
Approved
IDH2Small molecule
Acute Myeloid Leukemia
Idecabtagene vicleucel
Approved
BCMACell therapy
Multiple Myeloma
Ipilimumab
Approved
CTLA-4Monoclonal antibody
Non-Small Cell Lung Cancer
Lenalidomide
Approved
Cereblon E3 ubiquitin-ligase · Undisclosed / early pipelineSmall molecule
Multiple Myeloma
Mavacamten(Camzyos)
Approved
Cardiac myosin (inhibitor)Small molecule
Heart Failure
Nab-paclitaxel
Approved
TubulinSmall molecule
Non-Small Cell Lung CancerHR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Nivolumab
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Opdivo Qvantig
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
ozanimod(Zeposia)
Approved
S1P receptorSmall molecule
Inflammatory Bowel DiseaseMultiple Sclerosis
Ulcerative Colitis
Pomalidomide
Approved
Cereblon E3 ubiquitin-ligaseSmall molecule
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.